NO961180L - Transdermal device containing (E) -2- (p-fluorophenethyl) -3-fluoroallylamine for the treatment of Alzheimer's disease - Google Patents
Transdermal device containing (E) -2- (p-fluorophenethyl) -3-fluoroallylamine for the treatment of Alzheimer's diseaseInfo
- Publication number
- NO961180L NO961180L NO961180A NO961180A NO961180L NO 961180 L NO961180 L NO 961180L NO 961180 A NO961180 A NO 961180A NO 961180 A NO961180 A NO 961180A NO 961180 L NO961180 L NO 961180L
- Authority
- NO
- Norway
- Prior art keywords
- fluoroallylamine
- fluorophenethyl
- disease
- alzheimer
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Foreliggende oppfinnelse angår en metode for behandling av Alzheimers sykdom hos en pasient med behov derav, omfattende transdermal administrering til angitte pasient av en terapeutisk effektiv mengde av (E)-2-(p-fluor- fenetyl)-3-fluorallylamin eller et farmasøytisk akseptabelt salt derav. Også tilveiebrakt er en transdermal anordning for administrering av (E)-2- (p-fluorfenetyl)-3-fluorallylamin eller et farmasøytisk akseptabelt salt derav.The present invention relates to a method of treating Alzheimer's disease in a patient in need thereof, comprising transdermal administration to said patient of a therapeutically effective amount of (E) -2- (p-fluorophenethyl) -3-fluoroallylamine or a pharmaceutically acceptable salt thereof. Also provided is a transdermal device for administering (E) -2- (p-fluorophenethyl) -3-fluoroallylamine or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12719093A | 1993-09-24 | 1993-09-24 | |
PCT/US1994/009517 WO1995008325A1 (en) | 1993-09-24 | 1994-08-23 | Transdermal device containing (e)-2-(p-fluorophenethyl)-3-fluoroallylamine for the treatment of alzheimer's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
NO961180D0 NO961180D0 (en) | 1996-03-22 |
NO961180L true NO961180L (en) | 1996-03-22 |
Family
ID=22428772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO961180A NO961180L (en) | 1993-09-24 | 1996-03-22 | Transdermal device containing (E) -2- (p-fluorophenethyl) -3-fluoroallylamine for the treatment of Alzheimer's disease |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0720475A1 (en) |
JP (1) | JPH09505276A (en) |
CN (1) | CN1131390A (en) |
AU (1) | AU684545B2 (en) |
CA (1) | CA2172605A1 (en) |
HU (1) | HUT75877A (en) |
IL (1) | IL111017A0 (en) |
NO (1) | NO961180L (en) |
WO (1) | WO1995008325A1 (en) |
ZA (1) | ZA947262B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100479405B1 (en) * | 2002-05-24 | 2005-03-30 | 주식회사 싸이제닉 | Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease |
WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4861800A (en) * | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
ATE147978T1 (en) * | 1992-05-27 | 1997-02-15 | Merrell Pharma Inc | USE OF (E)-2-(P-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
-
1994
- 1994-08-23 JP JP7509764A patent/JPH09505276A/en active Pending
- 1994-08-23 CA CA002172605A patent/CA2172605A1/en not_active Abandoned
- 1994-08-23 AU AU76364/94A patent/AU684545B2/en not_active Ceased
- 1994-08-23 WO PCT/US1994/009517 patent/WO1995008325A1/en not_active Application Discontinuation
- 1994-08-23 HU HU9600725A patent/HUT75877A/en unknown
- 1994-08-23 CN CN94193473A patent/CN1131390A/en active Pending
- 1994-08-23 EP EP94926566A patent/EP0720475A1/en not_active Withdrawn
- 1994-09-19 ZA ZA947262A patent/ZA947262B/en unknown
- 1994-09-21 IL IL11101794A patent/IL111017A0/en unknown
-
1996
- 1996-03-22 NO NO961180A patent/NO961180L/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU7636494A (en) | 1995-04-10 |
HU9600725D0 (en) | 1996-05-28 |
ZA947262B (en) | 1995-05-23 |
JPH09505276A (en) | 1997-05-27 |
NO961180D0 (en) | 1996-03-22 |
IL111017A0 (en) | 1994-11-28 |
CA2172605A1 (en) | 1995-03-30 |
CN1131390A (en) | 1996-09-18 |
EP0720475A1 (en) | 1996-07-10 |
AU684545B2 (en) | 1997-12-18 |
WO1995008325A1 (en) | 1995-03-30 |
HUT75877A (en) | 1997-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930702022A (en) | Treatment or prevention of type 1 diabetes by oral administration of insulin | |
DE69815122T2 (en) | SACCHARID-CONTAINING PREPARATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES | |
DE68919358D1 (en) | COMPOSITION FOR TREATING SCHIZOPHRENIA. | |
RU94027680A (en) | Parathyroid hormone and raloxifen for bone mass increase, pharmaceutical composition and method of osseous mass increase | |
HUT60630A (en) | Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature | |
FI935847A0 (en) | L-DOPA esterkompositioner | |
DK0833643T3 (en) | Formulations of anhydrous monosodium salt of alendronate and their use in the treatment of bone disorders | |
DE69424777T2 (en) | 3,4-DIARYLCHROMANE FOR TREATING DERMATITIS | |
NO20003313D0 (en) | Therapeutic agents | |
NO961180L (en) | Transdermal device containing (E) -2- (p-fluorophenethyl) -3-fluoroallylamine for the treatment of Alzheimer's disease | |
NO944524L (en) | Use of (E) -2- (p-fluorophenethyl) -3-fluoroallylamine in the treatment of Alzheimer's disease | |
HUP9903679A2 (en) | Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder | |
ATE331523T1 (en) | STATIN THERAPY TO IMPROVE MAINTAINING COGNITIVE FUNCTION | |
DE69233315D1 (en) | PHARMACEUTICAL LYSINE CONTAINING POLYPEPTIDE COMPOSITIONS AND METHOD FOR USE THEREOF | |
DE69800906T2 (en) | Use of olanzapine in the manufacture of a medicament for the treatment of cerebral focal ischemia | |
EA200200559A1 (en) | METHOD OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE CONDITIONS | |
EA199800941A1 (en) | THERAPEUTICALLY MEANS CONTAINING OXYGEN ANION-RADICALS AND / OR PRODUCTS OF THEIR SUBSEQUENTAL TURNING AND DIVISION AND THEIR APPLICATION FOR THE TREATMENT OF PARKINSON'S DISEASE | |
RU94037731A (en) | Method for treating multiple sclerosis | |
MY110416A (en) | Composition for the treatment of schizophrenia. |